Cardiovascular Protective Effect of Spironolactone in Hemodialysis

Phase 4

• Conditions: Hemodialysis

• Registration Number: NCT00277693
• Lead Sponsor: Universidad de los Andes, Chile

Brief Summary

The purpose of the present study is to determine if spironolactone is safe and effective in the treatment of cardiovascular complications in hemodialysis patients.

Detailed Description

Cardiovascular complications are common in dialysis patients and comprise up to 50% of deaths in end-stage renal disease population. Hypertension and left ventricle hypertrophy occur in more than 70% of patients undergoing long-term hemodialysis therapy, and both contributes to mortality and morbidity.Recent clinical trials in chronic heart failure and post miocardial infarct heart failure patients have demonstrated a beneficial effect of a mineralocorticoid receptor blocker spironolactone, in adittion to standard therapy (RALES AND EPHESUS studies). The aim of the present study is to evaluate spironolactone treatment in hemodialysis patients.

Study Timeline

• Status Verified: 2005-12
• Study First Submitted: 2006-01-12
• Study First Submitted QC: 2006-01-12
• Last Update Submitted: 2006-01-12
• Study First Posted: 2006-01-16
• Last Update Posted: 2006-01-16

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

chronic hemodialysys (> 3 months) anuria (diuresis <200 mL/day) -

Exclusion Criteria

Liver failure Insulin dependent diabetes Treatment with adrenergic beta blockers or agonists Treatment with converting-enzime blocker or angiotensin receptor antagonists Cancer

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (1)

Clinica Davila; 🇨🇱 Santiago, Chile